Valeant Defends Itself As Legal Structures Test New LimitsMark Melin
Saying Citron Research’s motivation for issuing research that shined a spotlight on potential issues at Valeant Pharmaceuticals, Mike Pearson, Valeant's chief executive officer, characterized the short-seller's research as “similar to someone running into a theater and yelling fire.” The report, issued late . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click chat